| 1.91 Data as of May 23 |  +0.11 / +6.11%Today’s Change | 1.55 Today|||52-Week Range 3.40 | -22.98% Year-to-Date |
| CE Mark for Abbott's Xience Xpedition 48 - Analyst Blog May 22 / Zacks.com |
| Previous close | 1.80 |
| Today’s open | 1.82 |
| Day’s range | 1.82 - 2.00 |
| Volume | 82,754 |
| Average volume (3 months) | 48,655 |
| Market cap | $49.2M |
| Dividend yield | -- |
| Earnings growth (last year) | -35.80% |
| Earnings growth (this year) | +23.92% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -23.93% |
| P/E ratio | NM |
| Price/Sales | 4.64 |
| Price/Book | 2.33 |
| Today’s change | Today’s % change | |
|---|---|---|
| LCMDLife Care Medical De... | +0.02 | +1.50% |
| MELAMELA Sciences Inc | +0.03 | +2.78% |
| UPIUroplasty Inc | +0.02 | +0.80% |
| BVXBovie Medical Corp | 0.00 | 0.00% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.18 |
| Annual revenue (last year) | $14.6M |
| Annual profit (last year) | -$29.9M |
| Net profit margin | -205.13% |
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Kenneth Michael Reali |
CFO, Executive VP & Head-Investor Relations Joseph P. Slattery, CPA |
Corporate headquarters Wilmington, North Carolina |
.
